Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: Preliminary findings and a discussion of therapeutic mechanisms

Bipolar Disorders

Volumn 10, Issue 8, 2008, Pages 856-866

  Mallinger, Alan G ^a,b   Thase, Michael E ^b,c   Haskett, Roger ^b   Buttenfield, Joan ^b   Luckenbaugh, David A ^a   Frank, Ellen ^b   Kupfer, David J ^b   Manji, Husseini K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antimanic; Bipolar disorder; Lithium; Mania; Protein kinase C; Verapamil

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; LITHIUM CARBONATE; LITHIUM SALT; LORAZEPAM; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; PROTEIN KINASE C; RISPERIDONE; TAMOXIFEN; THIORIDAZINE; VERAPAMIL;

ADULT; AGITATION; ANTIMANIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVENING DOSAGE; FEMALE; HUMAN; INSOMNIA; MALE; MANIA; MENTAL DISEASE; MONOTHERAPY; MORNING DOSAGE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; PERPHENAZINE; PSYCHIATRIC STATUS RATING SCALES; VERAPAMIL;

EID: 56349172190     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2008.00636.x     Document Type: Article

References (68)

1. Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord 2000; 2: 108-119.
2. Keck PE Jr, Mendlwicz J, Calabrese JR et al. A review of randomized, controlled clinical trials in acute mania. J Affect Disord 2000; 59(Suppl. 1): S31-S37.
3. Post RM, Frye MA, Denicoff KD et al. Emerging trends in the treatment of rapid cycling bipolar disorder: A selected review. Bipolar Disord 2000; 2: 305-315.
4. Manna V. Bipolar affective disorders and the role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion. Minerva Med 1991; 82: 757-763.
5. Dubovsky S. Rapid cycling bipolar disease: New concepts and treatments. Curr Psychiatry Rep 2001; 3: 451-462.
6. Wisner KL, Peindl KS, Perel JM, Hanusa BH, Piontek CM, Baab S. Verapamil treatment for women with bipolar disorder. Biol Psychiatry 2002; 51: 745-752.
7. Yingling DR, Utter G, Vengalil S, Mason B. Calcium channel blocker, nimodipine, for the treatment of bipolar disorder during pregnancy. Am J Obstet Gynecol 2002; 187: 1711-1712.
8. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M. Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res 2000; 93: 83-87.
9. Dubovsky SL, Christiano J, Daniell LC et al. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 1989; 46: 632-638.
10. Tanaka Y, Kashiwagi A, Ogawa T et al. Effect of verapamil on cardiac protein kinase C activity in diabetic rats. Eur J Pharmacol 1991; 200: 353-356.
11. DePetrillo PB, Abernethy DR, Wainer IW, Andrawis NS. Verapamil decreases lymphocyte protein kinase C activity in humans. Clin Pharmacol Ther 1994; 55: 44-49.
12. Hoffman S, Gopalakrishna R, Gundimeda U et al. Verapamil inhibits proliferation, migration and protein kinase C activity in human retinal pigment epithelial cells. Exp Eye Res 1998; 67: 45-52.
13. Birnbaum SG, Yuan PX, Wang M et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004; 306: 882-884.
14. Einat H, Manji HK. Cellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry 2006; 59: 1160-1171.
15. Einat H, Yuan P, Szabo S, Dogra S, Manji H. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: Implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; 55: 123-131.
16. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the alpha isozyme. J Neurochem 1993; 61: 2303-2310.
17. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994; 63: 2361-2364.
18. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52: 531-543.
19. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57: 95-97.
20. Kulkarni J, Garland KA, Scaffidi A et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31: 543-547.
21. Zarate CA Jr, Singh JB, Carlson PJ et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 2007; 9: 561-570.
22. Baum AE, Akula N, Cabanero M et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197-207.
23. Frank E, Kupfer DJ, Thase ME et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62: 996-1004.
24. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ. Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969; 148: 87-98.
25. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 1979; 59: 420-430.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23: 56-62.
27. Thase ME, Carpenter L, Kupfer DJ, Frank E. Clinical significance of reversed vegetative subtypes of recurrent major depression. Psychopharmacol Bull 1991; 27: 17-22.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology: DHEW Publication No. (ADM) 76-338. Rockville, Maryland: US Department of Health, Education, and Welfare, 1976: 217-222.
29. Price WA, Shalley JE. Lithium-verapamil toxicity in the elderly. J Am Geriatr Soc 1987; 35: 177-178.
30. Helmuth D, Ljaljevic Z, Ramirez L, Meltzer HY. Choreoathetosis induced by verapamil and lithium treatment. J Clin Psychopharmacol 1989; 9: 454-455.
31. Dubovsky S, Franks R, Allen S. Verapamil: A new antimanic drug with potential interactions with lithium [see comment]. J Clin Psychiatry 1989; 48: 371-372.
32. Price WA, Giannini AJ. Neurotoxicity caused by lithium-verapamil synergism. J Clin Pharmacol 1986; 26: 717-719.
33. Wright BA, Jarrett DB. Lithium and calcium channel blockers: Possible neurotoxicity. Biol Psychiatry 1991; 30: 635-636.
34. Berk M, Bodemer W, van Oudenhove T, Butkow N. The platelet intracellular calcium response to serotonin is augmented in bipolar manic and depressed patients. Human Psychopharmacol 1995; 10: 189-193.
35. Hough C, Lu SJ, Davis CL, Chuang DM, Post RM. Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 1999; 46: 247-255.
36. Dubovsky SL, Murphy J, Thomas M, Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 1992; 149: 118-120.
37. Emamghoreishi M, Schlichter L, Li PP et al. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry 1997; 154: 976-982.
38. Wasserman MJ, Warsh JJ, Li PP, Pennefather PS, Sibony D. Hyperactive intracellular calcium mobilization in beta lymphoblasts from patients with bipolar 1 disorder. Biol Psychiatry 2003; 53(Suppl): 79S.
39. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980; 255: 10896-10901.
40. Sherman WR, Leavitt AL, Honchar MP, Hallcher LM, Phillips BE. Evidence that lithium alters phosphoinositide metabolism: Chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat. J Neurochem 1981; 36: 1947-1951.
41. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982; 206: 587-595.
42. Michell R. A link between lithium, lipids and receptors? Trends Biochem Sci 1982; 7: 387-388.
43. Drummond AH. Lithium affects G-protein receptor coupling. Nature 1988; 331: 388.
44. Avissar S, Schreiber G, Danon A, Belmaker RH. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988; 331: 440-442.
45. Wasserman MJ, Corson TW, Sibony D et al. Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacology 2004; 29: 759-769.
46. Pazzaglia PJ, Post RM, Ketter TA et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404-413.
47. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9: 161-167.
48. Manji H, Lenox R. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-1351.
49. Wang JF, Asghari V, Rockel C, Young LT. Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience 1999; 91: 771-776.
50. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2000; 2: 217-236.
51. Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992; 570: 333-340.
52. Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: Fifty-year update. J Clin Psychiatry 2000; 61(Suppl. 9): 5-15.
53. Manji HK, Chen G. Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders. Current Psychiatry Rep 2000; 2: 479-489.
54. Manji HK, Lenox RH. Signaling: Cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000; 48: 518-530.
55. Watson DG, Watterson JM, Lenox RH. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: A property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 1998; 285: 307-316.
56. Manji H, Chen G, Hsiao J, Masana M, Moore G, Potter W. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. In: Manji HK, Bowden CL, Belmaker RH, eds. Bipolar Medications: Mechanisms of Action. 1st edn. Washington, DC: American Psychiatric Press; 2000: 129-177.
57. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59: 1006-1020.
58. Cowell RM, Kantor L, Hewlett GH, Frey KA, Gnegy ME. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol 2000; 389: 59-65.
59. Giambalvo CT. Protein kinase C and dopamine transport - 2. Effects of amphetamine in vitro. Neuropharmacology 1992; 31: 1211-1222.
60. Giambalvo CT. Protein kinase C and dopamine transport - 1. Effects of amphetamine in vivo. Neuropharmacology 1992; 31: 1201-1210.
61. Gnegy ME, Hong P, Ferrell ST. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 1993; 20: 289-298.
62. Iwata S, Hewlett GH, Gnegy ME. Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse 1997; 26: 281-291.
63. Iwata SI, Hewlett GH, Ferrell ST, Kantor L, Gnegy ME. Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J Pharmacol Exp Ther 1997; 283: 1445-1452.
64. Friedman E, Hoau Yan W, Levinson D, Connell TA, Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993; 33: 520-525.
65. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996; 40: 568-575.
66. Wang H, Friedman E. Increased association of brain protein kinase C with the receptor for activated C kinase-1 (RACK1) in bipolar affective disorder. Biol Psychiatry 2001; 50: 364-370.
67. Topham MK, Prescott SM. Mammalian diacylglycerol kinases, a family of lipid kinases with signaling functions. J Biol Chem 1999; 274: 11447-11450.
68. Consortium TWTCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678.